JP6918003B2 - 創傷治癒のための幹細胞 - Google Patents

創傷治癒のための幹細胞 Download PDF

Info

Publication number
JP6918003B2
JP6918003B2 JP2018538137A JP2018538137A JP6918003B2 JP 6918003 B2 JP6918003 B2 JP 6918003B2 JP 2018538137 A JP2018538137 A JP 2018538137A JP 2018538137 A JP2018538137 A JP 2018538137A JP 6918003 B2 JP6918003 B2 JP 6918003B2
Authority
JP
Japan
Prior art keywords
cells
cell
wound
composition according
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018538137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506396A5 (enExample
JP2019506396A (ja
Inventor
エルノウト ルトゥン，
エルノウト ルトゥン，
ロバート ジェイ． ディーンズ，
ロバート ジェイ． ディーンズ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of JP2019506396A publication Critical patent/JP2019506396A/ja
Publication of JP2019506396A5 publication Critical patent/JP2019506396A5/ja
Application granted granted Critical
Publication of JP6918003B2 publication Critical patent/JP6918003B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018538137A 2016-01-21 2016-02-12 創傷治癒のための幹細胞 Expired - Fee Related JP6918003B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281334P 2016-01-21 2016-01-21
US62/281,334 2016-01-21
PCT/US2016/017848 WO2017127123A1 (en) 2016-01-21 2016-02-12 Stem cells for wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116882A Division JP2020172536A (ja) 2016-01-21 2020-07-07 創傷治癒のための幹細胞

Publications (3)

Publication Number Publication Date
JP2019506396A JP2019506396A (ja) 2019-03-07
JP2019506396A5 JP2019506396A5 (enExample) 2019-04-18
JP6918003B2 true JP6918003B2 (ja) 2021-08-11

Family

ID=59360064

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018538137A Expired - Fee Related JP6918003B2 (ja) 2016-01-21 2016-02-12 創傷治癒のための幹細胞
JP2020116882A Withdrawn JP2020172536A (ja) 2016-01-21 2020-07-07 創傷治癒のための幹細胞
JP2022129977A Pending JP2022163207A (ja) 2016-01-21 2022-08-17 創傷治癒のための幹細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020116882A Withdrawn JP2020172536A (ja) 2016-01-21 2020-07-07 創傷治癒のための幹細胞
JP2022129977A Pending JP2022163207A (ja) 2016-01-21 2022-08-17 創傷治癒のための幹細胞

Country Status (11)

Country Link
US (2) US10967006B2 (enExample)
EP (1) EP3405566B1 (enExample)
JP (3) JP6918003B2 (enExample)
KR (1) KR20180102661A (enExample)
CN (1) CN108884437A (enExample)
AU (2) AU2016387339B2 (enExample)
CA (1) CA3012330A1 (enExample)
HK (1) HK1256413A1 (enExample)
NZ (1) NZ745530A (enExample)
SG (2) SG11201806245TA (enExample)
WO (1) WO2017127123A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2568991B3 (en) 2010-05-12 2018-11-28 ABT Holding Company Modulation of splenocytes in cell therapy
EP3795159A1 (en) 2013-04-12 2021-03-24 Houston Methodist Hospital Improving organs for transplantation
SG11201806245TA (en) * 2016-01-21 2018-08-30 Abt Holding Co Stem cells for wound healing
KR102188572B1 (ko) * 2017-09-25 2020-12-09 사회복지법인 삼성생명공익재단 뇌척수액을 포함하는 줄기세포 투여 제형 및 그의 제조방법
US20240389931A1 (en) * 2020-01-23 2024-11-28 Precision Healing LLC Wound care diagnosis with fluorescence signatures
US20220117491A1 (en) * 2020-01-23 2022-04-21 Precision Healing, Inc. Multispectral sample analysis using fluorescence signatures
US20240245346A1 (en) * 2020-01-23 2024-07-25 Precision Healing, Inc. Image analysis using skin wound factors
EP4638696A1 (en) 2022-12-27 2025-10-29 AVITA Medical Americas, LLC System for automated preparation of a regenerative epidermal suspension and related methods of use

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
CA2123094C (en) 1991-11-06 1999-08-10 Paulo N. Correa Cell culture medium
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
US5906934A (en) 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US6653134B2 (en) 1995-03-28 2003-11-25 Cp Hahnemann University Isolated stromal cells for use in the treatment of diseases of the central nervous system
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
US6077987A (en) 1997-09-04 2000-06-20 North Shore-Long Island Jewish Research Institute Genetic engineering of cells to enhance healing and tissue regeneration
AU758073B2 (en) 1998-11-09 2003-03-13 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum free medium for chondrocyte-like cells
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050169896A1 (en) 1999-05-14 2005-08-04 Henry Ford Health System Bone marrow transplantation for treatment of stroke
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US8609412B2 (en) 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
JP5398941B2 (ja) 1999-08-05 2014-01-29 エイビーティー ホールディング カンパニー 多能性成体幹細胞およびそれを単離する方法
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
DE60041821D1 (de) 1999-09-24 2009-04-30 Cybios Llc Pluripotent embryonale stammzellen-ähnliche zellen, zusammensetzungen und ihre vervendungen
WO2001021767A2 (en) 1999-09-24 2001-03-29 Morphogen Pharmaceuticals, Inc. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US20030161817A1 (en) 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
ES2300320T3 (es) 2000-02-26 2008-06-16 Artecel, Inc. Celulas madre pluripotentes generadas a partir de celulas del estroma derivadas de tejido adiposo y sus usos.
WO2002009650A2 (en) 2000-07-31 2002-02-07 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2305795B1 (en) 2000-12-06 2019-07-03 Celularity, Inc. Method of collecting placental stem cells
JP2004529621A (ja) 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞
WO2002064755A2 (en) 2001-02-14 2002-08-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US7056738B2 (en) 2001-03-23 2006-06-06 Tulane University Early stage multipotential stem cells in colonies of bone marrow stromal cells
KR100449141B1 (ko) 2001-04-19 2004-09-21 (주)라이프코드 간엽 간세포를 신경세포로 분화시키는 방법
EP1383869B1 (en) 2001-04-24 2009-06-10 Dolores Baksh Progenitor cell populations, expansion thereof, and growth of non-hematopoietic cell types and tissues therefrom
US20030003090A1 (en) 2001-05-31 2003-01-02 Prockop Darwin J. Directed in vitro differentiation of marrow stromal cells into neural cell progenitors
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
WO2003064598A2 (en) 2002-01-25 2003-08-07 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US20060228798A1 (en) 2002-11-27 2006-10-12 Catherine Verfaillie Homologous recombination in multipotent adult progenitor cells
CA2809195C (en) 2003-04-01 2014-05-20 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
US20040235165A1 (en) 2003-05-19 2004-11-25 Darwin Prockop In vitro differentiation of adult stem cells
US8192348B2 (en) 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
WO2005003320A2 (en) 2003-07-02 2005-01-13 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
CA2536909A1 (en) 2003-08-29 2005-03-10 Regents Of The University Of Minnesota Kidney derived stem cells and methods for their isolation, differentiation and use
US7794706B2 (en) 2003-10-14 2010-09-14 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
AU2004296848A1 (en) 2003-12-04 2005-06-23 Regents Of The University Of Minnesota Compositions and methods for the treatment of lysosomal storage disorders
CA2558520C (en) 2004-03-05 2015-02-24 John E. Davies Serum-free suspension culture system for mesenchymal progenitor cells
EP2298863B1 (en) 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1737947B9 (en) 2004-04-21 2012-04-25 Regents Of The University Of Minnesota Mapc generation of lung tissue
WO2006047743A2 (en) * 2004-10-26 2006-05-04 Regents Of The University Of Minnesota Swine multipotent adult progenitor cells
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
EP2428563A1 (en) 2005-02-10 2012-03-14 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
CA2607213A1 (en) 2005-05-05 2006-11-16 Regents Of The University Of Minnesota Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells
AU2005331534B2 (en) 2005-05-05 2011-12-08 Regents Of The University Of Minnesota Use of MAPC or progeny therefrom to populate lymphohematopoietic tissues
WO2007016485A2 (en) 2005-07-29 2007-02-08 Athersys, Inc. Use of a gsk-3 inhibitor to maintain potency of cultured cells
US20080194024A1 (en) 2005-07-29 2008-08-14 Mays Robert W Culture of Non-Embryonic Cells at High Cell Density
NZ567082A (en) 2005-10-14 2012-08-31 Univ Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
US20220110982A1 (en) 2005-11-09 2022-04-14 Abt Holding Company Mapc treatment of brain injuries and diseases
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US8871198B2 (en) * 2006-03-29 2014-10-28 Stemnion, Inc. Methods related to wound healing
NZ744465A (en) * 2006-01-23 2023-04-28 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
US9005964B2 (en) 2006-11-24 2015-04-14 Regents Of The University Of Minnesota Endodermal progenitor cells
AU2008261901A1 (en) * 2007-06-08 2008-12-18 University Of Virginia Patent Foundation Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof
CA2712496C (en) 2008-01-18 2021-01-12 Wei-Shou Hu Stem cell aggregates and methods for making and using
NZ587598A (en) 2008-02-29 2012-10-26 Univ New York State Res Found Methods of increasing proliferation of a cell by administering a low magnitude, high frequency mechanical signal
US20110212062A1 (en) 2008-03-27 2011-09-01 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
GB2467982A (en) * 2008-05-08 2010-08-25 Coretherapix Slu Pluripotent adult stem cells
US9382514B2 (en) 2008-06-20 2016-07-05 Escape Therapeutics, Inc. Compositions comprising mesenchymal stem cell-derived fibroblasts
SG10201807935SA (en) 2008-09-04 2018-10-30 Abt Holding Co Use of stem cells to prevent neuronal dieback
EP2362899A1 (en) 2008-10-31 2011-09-07 Katholieke Universiteit Leuven Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
ES2690199T3 (es) 2009-07-21 2018-11-19 Abt Holding Company Uso de células madre para reducir la extravasación de leucocitos
EP3831930A1 (en) 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
WO2011060244A1 (en) 2009-11-12 2011-05-19 The Texas A & M University System Spheroidal aggregates of mesenchymal stem cells
WO2011062584A1 (en) 2009-11-19 2011-05-26 Regents Of The University Of Minnesota Reducing inflammation using cell therapy
US20150010610A1 (en) 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
US20110206647A1 (en) 2010-02-25 2011-08-25 Abt Holding Company Modulation of Angiogenesis
SG183497A1 (en) 2010-02-25 2012-09-27 Abt Holding Co Modulation of macrophage activation
WO2011106476A1 (en) 2010-02-25 2011-09-01 Abt Holding Company Modulation of microglia activation
CN102198156A (zh) 2010-03-26 2011-09-28 傅毓秀 用于治疗皮肤创伤之医药组合物
EP2568991B3 (en) 2010-05-12 2018-11-28 ABT Holding Company Modulation of splenocytes in cell therapy
WO2011143411A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US9090878B2 (en) 2010-06-17 2015-07-28 Katholieke Universiteit Leuven Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the methods, and methods for using the cells
WO2012009581A2 (en) 2010-07-14 2012-01-19 University Of Southern California Pharmaceutical compositions comprising gingiva-derived mesenchymal stem cells and methods of treating inflammation, wound healing and contact hypersensitivity
IL207586A0 (en) 2010-08-12 2010-12-30 Omrix Biopharmaceuticals Ltd A fibrin based therapeutic preparation and use thereof
CA2809245C (en) 2010-08-24 2020-07-14 Regents Of The University Of Minnesota Non-static suspension culture of cell aggregates
EP2670842A2 (en) 2011-01-31 2013-12-11 Katholieke Universiteit Leuven KU Leuven Research & Development Methods for making cells with an extra-embryonic endodermal precursor phenotype
SG10201914092XA (en) 2011-06-06 2020-03-30 ReGenesys BVBA Expansion of stem cells in hollow fiber bioreactors
EP3795159A1 (en) 2013-04-12 2021-03-24 Houston Methodist Hospital Improving organs for transplantation
ES2753323T3 (es) 2013-04-30 2020-04-08 Univ Leuven Kath Terapia celular para síndromes mielodisplásicos
US20160129043A1 (en) 2013-06-24 2016-05-12 University Of Southern California Composition of mesenchymal stem cells
WO2015017772A1 (en) 2013-08-01 2015-02-05 Parcell Laboratories, Llc Stem cell-based preparations and methods for dermal and connective tissue reconstruction and rejuvenation
US20160175485A1 (en) 2013-08-27 2016-06-23 The Regents Of The University Of California Combination therapy to promote wound healing
US20160069903A1 (en) 2014-09-10 2016-03-10 Fundació Institute De Ciències Foròniques Method for detecting cells
EP3291822A1 (en) 2015-05-05 2018-03-14 Katholieke Universiteit Leuven Improved methods for pancreatic islet transplantation
WO2017062035A1 (en) 2015-10-09 2017-04-13 Abt Holding Company Methods for enhancing proliferation of t regulatory cells
SG11201806245TA (en) * 2016-01-21 2018-08-30 Abt Holding Co Stem cells for wound healing
US20200246390A1 (en) 2019-02-01 2020-08-06 Abt Holding Company Multipotent adult projenitor cells for treatment of ich

Also Published As

Publication number Publication date
CA3012330A1 (en) 2017-07-27
HK1256413A1 (zh) 2019-09-20
US10967006B2 (en) 2021-04-06
US20170209493A1 (en) 2017-07-27
JP2022163207A (ja) 2022-10-25
US11918609B2 (en) 2024-03-05
AU2022211794A1 (en) 2022-08-25
KR20180102661A (ko) 2018-09-17
NZ745530A (en) 2023-03-31
SG11201806245TA (en) 2018-08-30
SG10201914102UA (en) 2020-03-30
WO2017127123A1 (en) 2017-07-27
JP2020172536A (ja) 2020-10-22
EP3405566B1 (en) 2023-10-18
US20220031756A1 (en) 2022-02-03
AU2016387339B2 (en) 2022-11-17
CN108884437A (zh) 2018-11-23
AU2016387339A1 (en) 2018-08-23
EP3405566A4 (en) 2019-07-31
EP3405566A1 (en) 2018-11-28
JP2019506396A (ja) 2019-03-07

Similar Documents

Publication Publication Date Title
JP6918003B2 (ja) 創傷治癒のための幹細胞
JP7535070B2 (ja) 虚血性疾患または虚血性損傷を処置するための心臓線維芽細胞由来細胞外マトリックスおよびその注射可能製剤
KR20190128622A (ko) 주산기 조직 유래된 중간엽 줄기 세포: 그의 제조 방법 및 용도
Kobayashi et al. On-site fabrication of Bi-layered adhesive mesenchymal stromal cell-dressings for the treatment of heart failure
JP2021105041A (ja) 熱傷の進行の緩和ならびに皮膚移植片の取り込みおよび治癒の改善における再生細胞の使用
KR102136450B1 (ko) 당뇨병성 피부 궤양 치료를 위한 다능성 줄기 세포
JP7029729B2 (ja) 血管障害の予防又は治療剤
AU2015284180B2 (en) Gonad-derived side population stem cells
Higginbotham Fat, fibroblasts, and fibrosis: how deposits of adipose tissue ameliorate dermal scarring
JP7213479B2 (ja) 皮膚保護剤
Winter Equine Endothelial Colony Forming Cells: In Vitro and In Vivo Analysis
Fukuta et al. Synergistic effect of ex-vivo quality and quantity cultured mononuclear cells and mesenchymal stem cell therapy in ischemic hind limb model mice
El-Hattab A little fat never hurt anybody: how fat can influence wound healing
CN108273063A (zh) 用于治疗急性肾脏损伤的医药组合物
EP4573184A1 (en) Pooled mesenchymal stromal cell derived cells, cell- and cell-free preparations thereof
US20160000874A1 (en) Modulating Ischemic Injury
Jadalannagari Decellularized Wharton's jelly matrix as a three dimensional scaffold for wound healing and hair regeneration applications
Farrokhi Evaluating the therapeutic use of Indoleamine 2, 3-dioxygenase (IDO) expressing allogenic dermal fibroblast populated within an acellular skin substitute as a wound coverage

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210720

R150 Certificate of patent or registration of utility model

Ref document number: 6918003

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees